Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Journal of Antimicrobial Chemotherapy(2024)10.1093/jac/dkae266Source: DataRank Database

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures is a research paper published in Journal of Antimicrobial Chemotherapy (2024). On theSindex it has a DataRank of 0. It has been cited 2 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access2 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.61)OA: hybridTopics (48)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Lindsey H. M. te Brake ORCID,Ann-Kathrin Lemm,Michael Höelscher ORCID,Elin M. Svensson ORCID,Christoph Hölscher ORCID

Live enrichment

PubMed:39110473 OpenAlex:https://openalex.org/W4401380366

German Center for Infection Research

Grant: TTU 02.710

German Center for Infection Research

Grant: 02.814

PanACEA 2

German Ministry for Education and Research

Swiss State Secretariat for Education, Research, and Innovation

Nederlandse Organisatie voor Wetenschappelijk Onderzoek

FWCI

0.61

Citation Percentile

0.7%

Citation Trend

2026

hybridLicense: cc-by

journalhttps://doi.org/10.1093/jac/dkae266

publisherhttps://doi.org/10.1093/jac/dkae266

publisherhttps://academic.oup.com/jac/article-pdf/79/10/2607/59460080/dkae266.pdf

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39110473

repositoryhttp://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-543699

Fields of Study

Tuberculosis Research and EpidemiologyInfectious Diseases and TuberculosisPhenothiazines and Benzothiazines Synthesis and ActivitiesAnimalsNitroimidazolesAntitubercular AgentsDiarylquinolinesMice, Inbred BALB CDisease Models, AnimalMycobacterium tuberculosisMiceOxazolesMoxifloxacinFemaleDrug Therapy, CombinationTuberculosis, Multidrug-ResistantOxazolidinonesPyrazinamideTreatment OutcomeIsoxazoles

MeSH Terms

MoxifloxacinAnimalsAntitubercular AgentsDisease Models, AnimalDrug Therapy, CombinationFemaleIsoxazolesMice, Inbred BALB CMycobacterium tuberculosisNitroimidazolesOxazolesPyrazinamideTreatment OutcomeTuberculosis, Multidrug-ResistantOxazolidinonesMiceDiarylquinolines

Keywords

BedaquilineMoxifloxacinTuberculosisMedicineDrugAntibioticsPharmacologyMicrobiologyMycobacterium tuberculosisBiologyPathology

Sustainable Development Goals

SDG 0: Good health and well-being